ATE431134T1 - Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt- blockcopolymeren - Google Patents

Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt- blockcopolymeren

Info

Publication number
ATE431134T1
ATE431134T1 AT06700417T AT06700417T ATE431134T1 AT E431134 T1 ATE431134 T1 AT E431134T1 AT 06700417 T AT06700417 T AT 06700417T AT 06700417 T AT06700417 T AT 06700417T AT E431134 T1 ATE431134 T1 AT E431134T1
Authority
AT
Austria
Prior art keywords
composition
pegt
controlled release
block copolymers
release compositions
Prior art date
Application number
AT06700417T
Other languages
English (en)
Inventor
Anne Bechet
Dijkhuizen-Radersma Riemke Van
Martin Stigter
Jeroen Bezemer
Original Assignee
Biolex Therapeutics Inc
Octoplus Polyactive Sciences B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics Inc, Octoplus Polyactive Sciences B filed Critical Biolex Therapeutics Inc
Application granted granted Critical
Publication of ATE431134T1 publication Critical patent/ATE431134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06700417T 2005-01-07 2006-01-06 Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt- blockcopolymeren ATE431134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075043A EP1679065A1 (de) 2005-01-07 2005-01-07 Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
PCT/NL2006/000006 WO2006085747A1 (en) 2005-01-07 2006-01-06 Controlled release compositions for interferon based on pegt/pbt block copolymers

Publications (1)

Publication Number Publication Date
ATE431134T1 true ATE431134T1 (de) 2009-05-15

Family

ID=34937981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06700417T ATE431134T1 (de) 2005-01-07 2006-01-06 Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt- blockcopolymeren

Country Status (23)

Country Link
US (3) US7736674B2 (de)
EP (4) EP1679065A1 (de)
JP (2) JP2008526837A (de)
KR (2) KR101354521B1 (de)
CN (2) CN101791396A (de)
AT (1) ATE431134T1 (de)
AU (2) AU2006213168B2 (de)
BR (1) BRPI0606514A2 (de)
CA (1) CA2594434A1 (de)
CY (1) CY1109297T1 (de)
DE (1) DE602006006797D1 (de)
DK (1) DK1843749T3 (de)
ES (1) ES2327267T3 (de)
HR (1) HRP20090434T1 (de)
IL (2) IL184431A (de)
MX (1) MX2007008293A (de)
PL (1) PL1843749T3 (de)
PT (1) PT1843749E (de)
RS (1) RS51129B (de)
RU (2) RU2409348C2 (de)
SG (1) SG158856A1 (de)
SI (1) SI1843749T1 (de)
WO (1) WO2006085747A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
EP2055299A1 (de) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Verfahren zur Herstellung von Polymermikropartikeln
CN102215821B (zh) 2007-10-23 2013-05-08 皇家飞利浦电子股份有限公司 用于制备聚合物微颗粒的方法
BRPI0910198A2 (pt) * 2008-06-30 2016-01-12 Silenseed Ltd composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
MX366228B (es) * 2011-03-25 2019-07-03 Selecta Biosciences Inc Nanoportadores sinteticos de liberacion mediada por osmosis.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
ES2919874T3 (es) 2014-09-24 2022-07-28 Vital Beverages Global Inc Composiciones y métodos para el suministro selectivo en el tubo gastrointestinal
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2021009040A1 (en) 2019-07-12 2021-01-21 Basf Se Process for producing microparticles laden with a volatile organic active
WO2025116554A1 (ko) * 2023-11-28 2025-06-05 에이비온 주식회사 인터페론 입실론의 신규한 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (de) * 1962-07-11
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
WO1993021858A1 (en) 1992-04-24 1993-11-11 Osteotech, Inc. Devices for preventing tissue adhesion
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
DE69819145T2 (de) * 1997-04-17 2004-08-19 Amgen Inc., Thousand Oaks Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
JP2001521006A (ja) * 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1145713A4 (de) * 1999-01-12 2003-08-06 Kyowa Hakko Kogyo Kk Telomerase-inhibitoren
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
PL352499A1 (en) 1999-07-15 2003-08-25 Takeda Chemical Industries Ltd Compositions of prolonged active substance release, method of obtaining them and their applications
EP1090928B1 (de) 1999-09-30 2004-05-26 Chienna B.V. Mit bioaktiven Mitteln beladene Polymeren
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) * 2000-11-13 2010-10-06 日東電工株式会社 多孔質ポリイミドの製造方法及び多孔質ポリイミド
PL363716A1 (en) 2000-12-13 2004-11-29 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
RU2191012C1 (ru) * 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003041689A1 (en) * 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
EP1466596B8 (de) 2001-12-26 2017-01-11 Takeda Pharmaceutical Company Limited Mikrosphäre und verfahren zu deren herstellung
KR101041767B1 (ko) 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
CN1852687B (zh) 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis

Also Published As

Publication number Publication date
AU2010224413A1 (en) 2010-10-14
US20100074868A1 (en) 2010-03-25
EP2266535A3 (de) 2011-06-15
BRPI0606514A2 (pt) 2010-01-19
AU2010224413B2 (en) 2012-03-22
HK1152644A1 (en) 2012-03-09
US7867518B2 (en) 2011-01-11
EP2266535A2 (de) 2010-12-29
PL1843749T3 (pl) 2009-10-30
PT1843749E (pt) 2009-08-17
ES2327267T3 (es) 2009-10-27
KR20100109983A (ko) 2010-10-11
KR20070118225A (ko) 2007-12-14
EP2266535B1 (de) 2013-03-06
RS51129B (sr) 2010-10-31
IL184431A0 (en) 2007-10-31
CN101137349B (zh) 2013-01-02
EP1843749B1 (de) 2009-05-13
JP2011016836A (ja) 2011-01-27
EP1886668A1 (de) 2008-02-13
IL184431A (en) 2012-03-29
DK1843749T3 (da) 2009-09-07
IL208175A0 (en) 2010-12-30
EP1886668B1 (de) 2012-11-14
US20080008733A1 (en) 2008-01-10
SI1843749T1 (sl) 2009-10-31
US8163307B2 (en) 2012-04-24
RU2409348C2 (ru) 2011-01-20
DE602006006797D1 (de) 2009-06-25
HRP20090434T1 (hr) 2009-09-30
SG158856A1 (en) 2010-02-26
EP1843749A1 (de) 2007-10-17
CA2594434A1 (en) 2006-08-17
JP2008526837A (ja) 2008-07-24
RU2007130090A (ru) 2009-02-20
CN101137349A (zh) 2008-03-05
JP4887542B2 (ja) 2012-02-29
EP1679065A1 (de) 2006-07-12
CY1109297T1 (el) 2014-07-02
AU2006213168B2 (en) 2011-09-15
US20090226532A1 (en) 2009-09-10
MX2007008293A (es) 2007-12-07
US7736674B2 (en) 2010-06-15
WO2006085747A1 (en) 2006-08-17
RU2010138739A (ru) 2012-03-27
CN101791396A (zh) 2010-08-04
AU2006213168A1 (en) 2006-08-17
KR101354521B1 (ko) 2014-01-22

Similar Documents

Publication Publication Date Title
IL184431A0 (en) Controlled release compositions for interferon based on pegt-pbt block copolymers
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
UA95225C2 (ru) Модифицированный полимером фактор viii для лечения гемофилии, способ его получения
ATE505551T1 (de) Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
NZ580686A (en) Modified interferon beta polypeptides and their uses
BRPI0607988A2 (pt) composto, composição farmacêutica, e método para induzir apoptose em uma célula
EP1721625A3 (de) Bioabbaubare medizinische Vorrichtungen mit verbesserter mechanischer Festigkeit und pharmakologischer Funktion
EA200700435A1 (ru) Рентгеноконтрастные полимерные стенты
IL213319A (en) Polylysis peptides for use in the treatment of bacterial infections
ATE531374T1 (de) Vorrichtung auf polymerbasis mit verzögerter freisetzung
DE69819343D1 (de) Zusammensetzungen und ihre verwendung zur verhütung von verklebungen zwischen körpergewebe
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
ATE533514T1 (de) Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern
ATE465205T1 (de) Polyglutamat-aminosäure-konjugate und verfahren
FR2824329B1 (fr) Compositions de polymeres antistatique
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ATE417618T1 (de) Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
BRPI0516568A (pt) biomateriais consistindo em ácido hialurÈnico sulfatado e gelana, bem como composição farmacêutica e uso dos mesmos
SE0301431D0 (sv) Novel antimicrobial peptides
DE602004021501D1 (de) Gegenüber ionisierender strahlung stabile polyarylestercarbonatzusammensetzungen
ATE528343T1 (de) Teilkristallines polymer enthaltende zusammensetzung und daraus hergestellter artikel
AU2003251728A8 (en) Placental growth factor as a target for the treatment of osteoporosis
DK1633440T3 (da) Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1843749

Country of ref document: EP